Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Unveiling the Limit-Up | High Demand and Prosperity! The order book for 3 stocks each exceeds 300 million yuan
As of today’s close (April 1), excluding newly listed shares that haven’t opened to trading yet, there are more than 4,400 stocks that rose, accounting for over 81%. More than 880 stocks fell, and over 100 stocks ended flat. Among them, there are 65 stocks that closed with their gains locked at the daily limit-up, and 15 stocks at the limit-down. In addition, 43 stocks failed to complete their limit-up bid lock, and the overall limit-up lock-in rate is 60.19%.
According to Securities Times · Data Bao statistics, among the stocks that were locked at the limit-up, there are relatively more stocks in the pharmaceutical and biological products, machinery and equipment, and construction and decoration sectors—15, 5, and 5 stocks respectively.
By the number of consecutive limit-up days, Tianjin Pharmaceuticals has already logged four consecutive daily limit-up boards, the most among all. Several compute power leasing and optical module related stocks also rank near the top by the amount of the order backlog. The limit-up order funds for OReid, Minpu Optics & Electronics, and YD Ding? Co., Ltd. are 341 million yuan, 321 million yuan, and 314 million yuan respectively.
On the news front, on the evening of March 31, the first post-listing financial report released by Zhipu showed that in 2025 the company achieved total revenue of 724 million yuan, up 131.9% year over year. The full-year consolidated gross margin was 41%, far above industry levels. Notably, in the first quarter of 2026, Zhipu’s API call pricing increased by 83%. Even so, the market still shows a situation of tight supply relative to demand, with call volume growing by 400%.
Several innovative drug stocks that hit the limit-up also have order backlog amounts near the top, including Jiu’an Medical, Tianjin Pharmaceuticals, Qilaiying, Guangshengtang, and Wanze Co., Ltd., among others.
In terms of order backlog strength (order backlog volume as a proportion of circulating A-shares), Minpu Optics & Electronics, Xihua Technology, and Baiseng Co., Ltd. have relatively strong figures, at 6.27%, 3.71%, and 3.38% respectively.
Statement: All information contained in Data Bao does not constitute an investment recommendation. The stock market is risky; investors should exercise caution.
Proofread by: Tao Qian